Compare Stocks: VNDA, CALT, ANRO, and CRON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$34.22 -1.9%	$27.10	$3.35 ▼ $35.41	$1.37B	1.06	441,541 shs	313,918 shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRON Cronos Group	$3.22 -2.1%	$2.85	$2.28 ▼ $3.43	$1.22B	0.9	1.48 million shs	998,091 shs
VNDA Vanda Pharmaceuticals	$5.38 -3.4%	$5.62	$4.27 ▼ $9.94	$336.78M	0.64	1.04 million shs	915,748 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	+2.23%	+20.02%	+34.42%	+62.49%	+911.61%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CRON Cronos Group	+2.49%	+3.79%	+17.50%	+20.51%	+32.66%
VNDA Vanda Pharmaceuticals	+2.39%	+7.32%	+4.70%	-10.31%	+22.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$34.22 -1.9%	$27.10	$3.35 ▼ $35.41	$1.37B	1.06	441,541 shs	313,918 shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRON Cronos Group	$3.22 -2.1%	$2.85	$2.28 ▼ $3.43	$1.22B	0.9	1.48 million shs	998,091 shs
VNDA Vanda Pharmaceuticals	$5.38 -3.4%	$5.62	$4.27 ▼ $9.94	$336.78M	0.64	1.04 million shs	915,748 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	+2.23%	+20.02%	+34.42%	+62.49%	+911.61%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CRON Cronos Group	+2.49%	+3.79%	+17.50%	+20.51%	+32.66%
VNDA Vanda Pharmaceuticals	+2.39%	+7.32%	+4.70%	-10.31%	+22.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.55	Moderate Buy	$37.25	8.85% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CRON Cronos Group	2.40	Hold	$2.30	-28.57% Downside
VNDA Vanda Pharmaceuticals	2.50	Moderate Buy	$13.70	154.65% Upside

Current Analyst Ratings Breakdown

Latest VNDA, CALT, ANRO, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
8/13/2026	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$24.00 ➝ $26.00
8/13/2026	ANRO Alto Neuroscience	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $37.00
8/12/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/10/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$21.00 ➝ $20.00
8/10/2026	VNDA Vanda Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $12.00
7/29/2026	ANRO Alto Neuroscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/22/2026	ANRO Alto Neuroscience	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/17/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/17/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/4/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$5.59 per share	N/A
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CRON Cronos Group	$146.59M	8.14	$0.01 per share	262.42	$3.01 per share	1.07
VNDA Vanda Pharmaceuticals	$216.10M	1.51	N/A	N/A	$3.64 per share	1.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$63.24M	-$2.42	N/A	N/A	N/A	N/A	-46.46%	-39.09%	N/A
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CRON Cronos Group	-$9.45M	$0.20	16.10	N/A	N/A	39.08%	4.85%	4.62%	11/5/2026 (Estimated)
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	11/4/2026 (Estimated)

Latest VNDA, CALT, ANRO, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANRO Alto Neuroscience	-$0.7345	-$0.65	+$0.0845	-$0.65	N/A	N/A
8/6/2026	Q2 2026	CRON Cronos Group	$0.01	$0.09	+$0.08	$0.09	$44.20 million	$53.01 million
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.07	14.85	14.85
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CRON Cronos Group	N/A	16.18	15.25
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
CALT Calliditas Therapeutics AB (publ)	2.83%
CRON Cronos Group	8.71%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.25%
CALT Calliditas Therapeutics AB (publ)	2.20%
CRON Cronos Group	7.80%
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	39.24 million	34.83 million	N/A
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	No Data
CRON Cronos Group	450	370.73 million	341.81 million	Optionable
VNDA Vanda Pharmaceuticals	290	60.46 million	53.99 million	Optionable

VNDA, CALT, ANRO, and CRON Headlines

Recent News About These Companies

Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA

August 17 at 6:39 AM | marketbeat.com

AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA

August 17 at 3:04 AM | marketbeat.com

HC Wainwright Issues Negative Outlook for VNDA Earnings

August 14, 2026 | americanbankingnews.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 13, 2026 | marketbeat.com

Vanda (VNDA) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst

August 12, 2026 | marketbeat.com

B. Riley Financial Reiterates Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)

August 12, 2026 | americanbankingnews.com

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

August 11, 2026 | zacks.com

Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial

August 10, 2026 | marketbeat.com

Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA

August 9, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Arrowstreet Capital Limited Partnership Buys New Position in Vanda Pharmaceuticals Inc. $VNDA

August 6, 2026 | marketbeat.com

Vanda Pharmaceuticals Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Vanda Pharmaceuticals Balances Strong Growth With Rising Losses

August 5, 2026 | tipranks.com

Vanda: Q2 Earnings Snapshot

August 5, 2026 | chron.com

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2026 | zacks.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Releases Quarterly Earnings Results, Misses Expectations By $0.46 EPS

August 5, 2026 | marketbeat.com

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 5, 2026 | prnewswire.com

Renaissance Technologies LLC Raises Stake in Vanda Pharmaceuticals Inc. $VNDA

July 30, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo Finance

July 29, 2026 | finance.yahoo.com

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

July 29, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA, CALT, ANRO, and CRON Company Descriptions

Alto Neuroscience NYSE:ANRO

$34.22 -0.67 (-1.92%)

As of 03:58 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/19/2026

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Cronos Group NASDAQ:CRON

$3.22 -0.07 (-2.13%)

Closing price 04:00 PM Eastern

Extended Trading

$3.22 0.00 (0.00%)

As of 05:50 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Vanda Pharmaceuticals NASDAQ:VNDA

$5.38 -0.19 (-3.41%)

Closing price 04:00 PM Eastern

Extended Trading

$5.36 -0.02 (-0.37%)

As of 05:45 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNDA, CALT, ANRO, and CRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNDA, CALT, ANRO, and CRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNDA, CALT, ANRO, and CRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA, CALT, ANRO, and CRON Company Descriptions

Alto Neuroscience NYSE:ANRO

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Cronos Group NASDAQ:CRON

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNDA, CALT, ANRO, and CRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNDA, CALT, ANRO, and CRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNDA, CALT, ANRO, and CRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA, CALT, ANRO, and CRON Company Descriptions

Alto Neuroscience NYSE:ANRO

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Cronos Group NASDAQ:CRON

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools